2010
Outcomes After Simultaneous Pancreas and Kidney Transplantation and the Discriminative Ability of the C-peptide Measurement Pretransplant Among Type 1 and Type 2 Diabetes Mellitus
Chakkera HA, Bodner JK, Heilman RL, Mulligan DC, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Ray RM, Beck GL, Reddy KS. Outcomes After Simultaneous Pancreas and Kidney Transplantation and the Discriminative Ability of the C-peptide Measurement Pretransplant Among Type 1 and Type 2 Diabetes Mellitus. Transplantation Proceedings 2010, 42: 2650-2652. PMID: 20832562, PMCID: PMC3060052, DOI: 10.1016/j.transproceed.2010.04.065.Peer-Reviewed Original ResearchMeSH KeywordsAdultC-PeptideCreatinineDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic NephropathiesDiabetic RetinopathyFemaleFollow-Up StudiesGlycated HemoglobinGraft RejectionHumansKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPancreas TransplantationRetrospective StudiesSurvival AnalysisTissue DonorsConceptsEnd-stage renal diseaseType of diabetesC-peptideSimultaneous pancreasKidney transplantationPatient survivalGlutamic acid decarboxylase antibodiesType 2 diabetes mellitusDetectable C-peptideMean creatinine clearanceRenal Disease equationModification of DietBody mass indexC-peptide measurementsRegression survival analysisGlycosylate hemoglobinDiabetic ketoacidosisESRD patientsPancreas transplantationT2DM patientsCreatinine clearanceDecarboxylase antibodiesOral hypoglycemicsRenal replacementDiabetes mellitus
2009
Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match
Heilman R, Chakkera H, Mazur M, Petrides S, Moss A, Mekeel K, Mulligan D, Reddy K. Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match. Transplantation Proceedings 2009, 41: 303-306. PMID: 19249540, DOI: 10.1016/j.transproceed.2008.08.154.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumDrug Therapy, CombinationFollow-Up StudiesGraft SurvivalHistocompatibility TestingHumansImmunoglobulins, IntravenousImmunosuppressive AgentsKidney TransplantationPancreas TransplantationRetrospective StudiesSurvival AnalysisTime FactorsTreatment OutcomeConceptsAntibody-mediated rejectionLow-dose intravenous immunoglobulinAcute cellular rejectionIntravenous immunoglobulinStudy groupControl groupAllograft survivalMycophenolate mofetilRisk of AMRSimultaneous pancreas-kidney transplant recipientsPancreas-kidney transplant recipientsSimultaneous kidney-pancreas transplantationDose intravenous immunoglobulinKidney-pancreas transplantationPositive cross matchRabbit antithymocyte globulinActuarial patient survivalKidney allograft survivalKidney transplant recipientsPancreas allograft survivalAcute rejectionAntithymocyte globulinCellular rejectionSPKT recipientsKidney allografts
2006
Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation
Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V. Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation. American Journal Of Transplantation 2006, 6: 1957-1962. PMID: 16771808, DOI: 10.1111/j.1600-6143.2006.01411.x.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationHepatocellular carcinomaHCC candidatesCandidate survivalLiver transplantationMELD scoreStage T1Waiting listEnd-stage liver diseaseDonor liver transplantationT2 hepatocellular carcinomaOrgan allocation policyUNOS databaseLiver transplantLiver diseasePatient survivalUnited NetworkHCC patientsIncidence rateOrgan SharingSurvivalTransplantationCarcinomaDropout rateTime periodLiver Transplantation in the MELD Era: A Single-Center Experience
Sachdev M, Hernandez JL, Sharma P, Douglas DD, Byrne T, Harrison ME, Mulligan D, Moss A, Reddy K, Vargas HE, Rakela J, Balan V. Liver Transplantation in the MELD Era: A Single-Center Experience. Digestive Diseases And Sciences 2006, 51: 1070-1078. PMID: 16865573, DOI: 10.1007/s10620-006-8011-1.Peer-Reviewed Original ResearchMeSH KeywordsArizonaCarcinoma, HepatocellularFemaleHepatitis CHumansLiver DiseasesLiver NeoplasmsLiver TransplantationMaleMedical RecordsMiddle AgedOutcome Assessment, Health CareResource AllocationRetrospective StudiesRisk AssessmentSeverity of Illness IndexSurvival AnalysisTissue and Organ ProcurementWaiting ListsConceptsDeceased donor liver transplantationLiver transplantationTransplantation ratesEndstage Liver Disease (MELD) scoreImpact of MELDDonor liver transplantationLiver Disease scoreUnderlying liver diseaseSingle-center experienceHepatocellular carcinoma patientsHepatitis C virusNew allocation policyHCC candidatesMELD implementationNew MELDTimely transplantClinical deteriorationMELD eraCarcinoma patientsLiver diseaseHepatitis C virus groupC virusHCC patientsMayo ClinicDropout rateLiving donor liver transplantation for hepatitis C‐related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients
Guo L, Orrego M, Rodriguez‐Luna H, Balan V, Byrne T, Chopra K, Douglas DD, Harrison E, Moss A, Reddy KS, Williams JW, Rakela J, Mulligan D, Vargas HE. Living donor liver transplantation for hepatitis C‐related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transplantation 2006, 12: 560-565. PMID: 16555313, DOI: 10.1002/lt.20660.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationDonor liver transplantationLiver transplantationHistological recurrenceHepatitis CDeceased-donor liver transplantation (DDLT) recipientsEnd-stage liver disease (MELD) scoreDonor liver transplantation recipientsHepatitis C virus infectionKaplan-Meier survival analysisDetectable HCV RNAHistological recurrence rateC virus infectionGraft survival ratesLiver Disease scoreActivity of inflammationLiver transplantation recipientsStatistical differenceChild-TurcotteDDLT groupLDLT patientsPugh scoreRecurrent HCVLiver transplantYears posttransplantation
2004
Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy
Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy. Gastroenterology 2004, 127: s261-s267. PMID: 15508092, DOI: 10.1053/j.gastro.2004.09.040.Peer-Reviewed Original ResearchConceptsNumber of patientsHepatocellular cancerHCC patientsWaiting listLiver transplantationDeceased donorsExcellent long-term survivalPost-MELD eraAdvanced stage diseaseLiver transplant candidatesLong-term survivalHigh mortality rateProgression of HCCHCC recipientsPosttransplant survivalStage diseaseTransplant candidatesUnited NetworkDonor organsLower incidenceMortality ratePatientsAdvanced stageEarly assessmentTransplantation